405 related articles for article (PubMed ID: 34493493)
1. The Risk of Cutaneous Squamous Cell Carcinoma Among Patients with Type 2 Diabetes Receiving Hydrochlorothiazide: A Cohort Study.
de Haan-Du J; Landman GWD; Groenier KH; Vissers PAJ; Louwman MWJ; Kleefstra N; de Bock GH
Cancer Epidemiol Biomarkers Prev; 2021 Nov; 30(11):2114-2121. PubMed ID: 34493493
[TBL] [Abstract][Full Text] [Related]
2. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States.
Eworuke E; Haug N; Bradley M; Cosgrove A; Zhang T; Dee EC; Adimadhyam S; Petrone A; Lee H; Woodworth T; Toh S
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33733052
[TBL] [Abstract][Full Text] [Related]
3. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer.
Rouette J; Yin H; Pottegård A; Nirantharakumar K; Azoulay L
Drug Saf; 2021 Feb; 44(2):245-254. PubMed ID: 33104975
[TBL] [Abstract][Full Text] [Related]
4. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients.
Letellier T; Leborgne F; Kerleau C; Gaultier A; Dantal J; Ville S;
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1804-1813. PubMed ID: 33172936
[TBL] [Abstract][Full Text] [Related]
5. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy.
Patel BV; Remigio-Baker RA; Thiebaud P; Preblick R; Plauschinat C
BMC Fam Pract; 2008 Nov; 9():61. PubMed ID: 18990240
[TBL] [Abstract][Full Text] [Related]
6. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs.
Lin JJ; Chang HC; Ku CT; Chen HY
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(13):2926-34. PubMed ID: 27424996
[TBL] [Abstract][Full Text] [Related]
7. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy.
Krum H; Skiba M; Gilbert RE
Diabet Med; 2003 Sep; 20(9):708-12. PubMed ID: 12925048
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring.
Pareek AK; Messerli FH; Chandurkar NB; Dharmadhikari SK; Godbole AV; Kshirsagar PP; Agarwal MA; Sharma KH; Mathur SL; Kumbla MM
J Am Coll Cardiol; 2016 Feb; 67(4):379-389. PubMed ID: 26821625
[TBL] [Abstract][Full Text] [Related]
9. Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer.
Kreutz R; Algharably EAH; Douros A
J Hypertens; 2019 Oct; 37(10):1950-1958. PubMed ID: 31145177
[TBL] [Abstract][Full Text] [Related]
10. Low dose of hydrochlorothiazide, in combination with angiotensin receptor blocker, reduces blood pressure effectively without adverse effect on glucose and lipid profiles.
Fujiwara W; Izawa H; Ukai G; Yokoi H; Mukaide D; Kinoshita K; Morimoto S; Ishii J; Ozaki Y; Nomura M
Heart Vessels; 2013 May; 28(3):316-22. PubMed ID: 22447467
[TBL] [Abstract][Full Text] [Related]
11. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis.
Roush GC; Abdelfattah R; Song S; Ernst ME; Sica DA; Kostis JB
J Clin Hypertens (Greenwich); 2018 Oct; 20(10):1507-1515. PubMed ID: 30251403
[TBL] [Abstract][Full Text] [Related]
12. Risk of squamous cell carcinoma of the lip and cutaneous melanoma in older Australians using hydrochlorothiazide: A population-based case-control study.
Daniels B; Pearson SA; Vajdic CM; Pottegård A; Buckley NA; Zoega H
Basic Clin Pharmacol Toxicol; 2020 Oct; 127(4):320-328. PubMed ID: 32608576
[TBL] [Abstract][Full Text] [Related]
13. Risk of skin cancer in new users of thiazides and thiazide-like diuretics: a cohort study using an active comparator group.
Schneider R; Reinau D; Stoffel S; Jick SS; Meier CR; Spoendlin J
Br J Dermatol; 2021 Aug; 185(2):343-352. PubMed ID: 33609289
[TBL] [Abstract][Full Text] [Related]
14. Long-term safety and tolerability of the oral direct renin inhibitor aliskiren with optional add-on hydrochlorothiazide in patients with hypertension: a randomized, open-label, parallel-group, multicentre, dose-escalation study with an extension phase.
Sica D; Gradman AH; Lederballe O; Kolloch RE; Zhang J; Keefe DL
Clin Drug Investig; 2011 Dec; 31(12):825-37. PubMed ID: 22035463
[TBL] [Abstract][Full Text] [Related]
15. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
White WB; Davidai G; Schumacher H
J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698
[TBL] [Abstract][Full Text] [Related]
16. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
[TBL] [Abstract][Full Text] [Related]
17. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide.
Moore MJ; Gong Y; Hou W; Hall K; Schmidt SO; Curry RW; Beitelshees AL; Chapman A; Turner ST; Schwartz GL; Bailey K; Boerwinkle E; Gums JG; Cooper-DeHoff RM; Johnson JA
Pharmacotherapy; 2014 Nov; 34(11):1132-40. PubMed ID: 25202885
[TBL] [Abstract][Full Text] [Related]
18. Hydrochlorothiazide use and the risk of skin cancer in patients with hypertensive disorder: a nationwide retrospective cohort study from Korea.
Park E; Lee Y; Jue MS
Korean J Intern Med; 2020 Jul; 35(4):917-928. PubMed ID: 31842528
[TBL] [Abstract][Full Text] [Related]
19. Treatment of hypertension with thiazides: benefit or damage-effect of low- and high-dose thiazide diuretics on arterial elasticity and metabolic parameters in hypertensive patients with and without glucose intolerance.
Shargorodsky M; Boaz M; Davidovitz I; Asherov J; Gavish D; Zimlichman R
J Cardiometab Syndr; 2007; 2(1):16-23. PubMed ID: 17684458
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of olmesartan medoxomil 40 mg/hydrochlorothiazide 12.5 mg combination therapy versus olmesartan medoxomil 40 mg monotherapy in patients with moderate to severe hypertension: a randomized, double-blind, parallel-group, multicentre, multinational, phase III study.
Fogari R; Taddei S; Holm-Bentzen M; Baszak J; Melani L; Schumacher K
Clin Drug Investig; 2010; 30(9):581-97. PubMed ID: 20593911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
